AstraZeneca has become the latest big pharma company to devote new cash to its US manufacturing muscle this year as it ...

Vera Therapeutics appointed Amgen and Seagen alum Matt Skelton as EVP of commercial. Frank Lane was appointed SVP and head of ...

AstraZeneca PLC aims for $80 billion revenue by 2030 through strong growth in oncology, biopharmaceuticals, and rare diseases ...

AstraZeneca Plc is increasingly looking to the US for growth as its once fast-expanding China business faces challenges amid ...

The company is also raising its full-year guidance to $14.9 billion in adjusted EBITDA, an 8.8% increase from its last ...

AstraZeneca’s earnings were boosted by its oncology, cardiovascular, respiratory and immunology (R&I), and rare disease ...

AstraZeneca boss Pascal Soriot (pictured)) threw his weight behind its Chinese business despite the recent arrest of its boss ...

One investigation discussed during the call involves sales reps in China allegedly changing genetic testing results to secure reimbursement for Tagrisso.

AstraZeneca Plc isn’t the only health-care company facing compliance questions in China as concern continued to swirl about a probe into alleged legal breaches tied to drug importation and data ...

Shares in AstraZeneca were down 1.3 percent in midday deals on London's top-tier FTSE 100 index, which was trading one ...

The company said it aims to expand its U.S. presence by the end of 2026. The new spending will be for a research-and-development center in Cambridge, Mass.; manufacturing plants in Maryland and Texas, ...

STORY: Drugmaker AstraZeneca has lifted its annual sales and profit forecast for the second time this year, as third-quarter results beat estimates.It's been helped by strong demand for its cancer and ...